For example, given no clear standard-of-care approach for treating biochemical recurrence of prostate cancer, GLP-1R agonists could be studied in combination with androgen deprivation therapy or as a single agent therapy given pre-clinical evidence of activity independent of the androgen receptor axis. This evidence concerns the gene GLP1R and prostate carcinoma.